In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
You may also be interested in...
GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.
The Japanese drug firm is making a strong bid to make expensive drugs affordable in emerging markets like India. For those who cannot pay, the drug will be made available free of charge.
Amid a series of patent related setbacks faced by global drug firms, GSK has safeguarded Tykerb against Fresenius Kabi.